Effectiveness of venlafaxine in the treatment of alcohol dependence with comorbid depression;Efectividad de la venlafaxina en el tratamiento de la dependencia de alcohol con depresión comórbida

Actas Espanolas de Psiquiatria

Volumn 33, Issue 1, 2005, Pages 41-45

  Garcia Portilla M P ^a   Bascaran M T ^a   Saiz, P A ^a   Mateos, M ^b   Gonzalez Quiros M ^c   Perez P ^d   Avila J J ^e   Torres, M A ^f   Bombin B ^g   Caso, C ^h   Marin R ⁱ   Prieto, R ^j   Bobes, J ^a  

^a UNIVERSITY OF OVIEDO   (Spain)

^b Hospital Divino Valles   (Spain)

^c Clínica San Rafael   (Spain)

^d Hospital Provincial de Pontevedra   (Spain)

^e Hospital Provincial de Salamanca   (Spain)

^f U de Alcoholismo Y Toxicomanias   (Spain)

^g HOSPITAL CLÍNICO UNIVERSITARIO DE VALLADOLID   (Spain)

^h Servicio de Alcoholismo de Vitoria

ⁱ Hospital Provincial de Zaragoza   (Spain)

^j Wyeth Farma ^*  (Spain)

more..

Author keywords

Alcohol dependence; Depression; Treatment; Venlafaxine

Indexed keywords

VENLAFAXINE;

ADULT; AGE DISTRIBUTION; ALCOHOL CONSUMPTION; ALCOHOLISM; ARTICLE; COMORBIDITY; CONTROLLED STUDY; DIAGNOSTIC AND STATISTICAL MANUAL OF MENTAL DISORDERS; DIAGNOSTIC PROCEDURE; DISEASE SEVERITY; FAMILY; FOLLOW UP; HAMILTON SCALE; HEALTH STATUS; HUMAN; MAJOR CLINICAL STUDY; MAJOR DEPRESSION; OUTCOMES RESEARCH; OUTPATIENT; RATING SCALE; SOCIAL INTERACTION; STATISTICAL SIGNIFICANCE;

ADULT; ALCOHOLISM; ANTIDEPRESSIVE AGENTS, SECOND-GENERATION; CYCLOHEXANOLS; DEPRESSION; FEMALE; FOLLOW-UP STUDIES; HUMANS; MALE;

EID: 20144389829     PISSN: 11399287     EISSN: None     Source Type: Journal    
DOI: None     Document Type: Article

References (29)

1. Kessler RC, McGonagle KA, Zhao S, Nelson CB, Hughes M, Eshleman S, et al. Lifetime and 12-month prevalence of DSM-III-R psychiatric disorders in the United States. Results from the National Comorbidity Survey. Arch Gen Psychiatry 1994;51:8-19.
2. Thase ME, Salloum IM, Cornelius JD. Comorbid alcoholism and depression: treatment issues. J Clin Psychiatry 2001;62(Suppl.20):32-41.
3. Mason BJ, Kocsis JH, Ritvo EC, Cutler RB. A double-blind, placebo-controlled trial of desipramine for primary alcohol dependence stratified on the presence or absence of major depression. JAMA 1996;275(10)761-7.
4. Nunes EV, McGrath PJ, Quitkin FM, Stewart JP, Harrison W, Tricamo E, et al. Imipramine treatment of alcoholism with comorbid depression. Am J Psychiatry 1993;150(6):963-5.
5. Gual A, Balcells M, Torres M, Madrigal M, Díez T, Serrano L. Sertraline for the prevention of relapse in detoxicated alcohol dependent patients with a comorbid depressive disorder: a randomized controlled trial. Alcohol Alcoholism 2003;38(6):619-25.
6. Heinz A, Mann K, Winberger DR, Goldman D. Serotonergic dysfunction, negative mood states and response to alcohol. Alcoholism: Clinical and Experimental Research 2001;25:487-95.
7. Ciraulo DA, Jaffe JH. Tricyclic antidepressants in the treatment of depression associated with alcoholism. J Clin Psychopharmacol 1981;1(3):146-50.
8. Kranzler HR. Dual diagnosis and treatment. Substance abuse and comorbid medical and psychiatric disorders. New York: Marcel Dekker, 1988.
9. Cornelius JR, Salloum IM, Ehler JG, Jarrett PJ, Cornelius MD, Perel JM, et al. Fluoxetine in depressed alcoholics. A double-blind, placebo-controlled trial. Arch Gen Psychiatry 1997;54(8):700-5.
10. Cornelius JR, Salloum IM, Mezzich J, Cornelius MD, Fabrega H Jr., Ehler JG, et al. Disproportionate suicidality in patients with comorbid major depression and alcoholism. Am J Psychiatry 1995; 152(3):358-64.
11. Roy A. Placebo-controlled study of sertraline in depressed recently abstinent alcoholics. Biol Psychiatry 1998;44(7):633-7.
12. Pettinati HM, Volpicelli JR, Luck G, Kranzler HR, Rukstalis MR, Cnaan A. Double-blind clinical trial of sertraline treatment for alcohol dependence. J Clin Psychopharmacol 2001;21(2):143-53.
13. Roy-Byrne PP, Pages KP, Russo JE, Jaffe C, Blume AW, Kingsley E, et al. Nefazodone treatment of major depression in alcohol-dependent patients: a double-blind, placebo-controlled trial. J Clin Psychopharmacol 2000;20(2):129-36.
14. McDowell DM, Levin FR, Seracini AM, Nunes EV. Venlafaxine treatment of cocaine abusers with depressive disorders. Am J Drug Alcohol Abuse 2000;26(1):25-31.
15. Upadhyaya HP, Brady KT, Sethuraman G, Sonne SC, Malcolm R. Venlafaxine treatment of patients with comorbid alcohol/cocaine abuse and attention-deficit/hyperactivity disorder a pilot study. J Clin Psychopharmacol 2001;21(1):116-8.
16. Bobes J, González MP, Saiz PA, Bousoño M. Venlafaxine in the treatment of depression in alcoholic patients. Comunicación poster presentada en el 21st Congress of the CINP (Abstract PW 16008). Glasgow, 1997.
17. Foltin RW, Ward AS, Collins ED, Haney M, Hart CL, Fischman MW. The effects of Venlafaxine on the subjective, reinforcing, and cardiovascular effects of cocaine in opioid-dependent and non-opioid-dependent humans. Exp Clin Psychopharmacol 2003;11(2):123-30.
18. Hamilton M. A rating scale for depression. J Neurol Neurosurg Psychiatr 1960;23:56-62.
19. Bobes J, Bulbena A, Luque A, Dal-Ré R, Ballesteros J, Ibarra N, et al. Evaluación psicométrica comparativa de las versíones en español de 6, 17 y 21 items de la escala de valoración de Hamilton para la evaluación de la depresión. Med Clin (Barc) 2003;120:693-700.
20. Loranger AW, Sartorius N, Andreoli A, Berger P, Buchheim P, Channabasavanna SM, et al. The International Personality Disorder Examination. The World Health Organization/Alcohol, Drug Abuse, and Mental Health Administration international pilot study of personality disorders. Arch Gen Psychiatry 1994;51(3):215-24.
21. Kokkevi A, Hartgers C. European adaptation of a mulitidimensional assessment instrument for drug and alcohol dependence. Eur Addict Res 1995;1:208-10.
22. Guy W. Early Clinical Drug Evaluation (ECDEU) Assessment Manual. Rockville: National Institute of Mental Health, 1976.
23. Cunningham LA, Borison RL, Carman JS, Chouinard G, Crowder JE, Diamond Bl, et al. A comparison of venlafaxine, trazodone, and placebo in major depression. J Clin Psychopharmacol 1994;14(2):99-106.
24. Dierick M. An open-label evaluation of the long-term safety of oral venlafaxine in depressed elderly patients. Ann Clin Psychiatry 1996;8(3):169-78.
25. Einarson TR, Arikian SR, Casciano J, Doyle JJ. Comparison of extended-release venlafaxine, selective serotonin reuptake inhibitors, and tricyclic antidepressants in the treatment of depression: a meta-analysis of randomized controlled trials. Clin Ther 1999;21(2):296-308.
26. Ereshefsky L, Dugan D. Review of the pharmacokinetics, pharmacogenetics, and drug interaction potential of antidepressants: focus on venlafaxine. Depress Anxiety 2000;12(Suppl. 1):30-44.
27. Hackett D. Venlafaxine XR in the treatment of anxiety. Acta Psychiatr Scand 2000;(Suppl. 406):30-5.
28. Gorman JM, Papp LA. Efficacy of venlafaxine in mixed depression-anxiety states. Depress Anxiety 2000;12(Suppl. 1):77-80.
29. Blythe D, Hackett LP. Cardiovascular and neurological toxicity of venlafaxine. Hum Exp Toxicol 1999;18(5):309-13.